gold stocks postpage LB desk

Noxopharm to Commence Veyonda®’s Clinical Trial in COVID-19 Patients in Europe

  • September 04, 2020 01:45 PM AEST
  • Team Kalkine
Noxopharm to Commence Veyonda<sup>®</sup>’s Clinical Trial in COVID-19 Patients in Europe


  • Noxopharm has been granted official approval for the use of Veyonda® in hospitalised COVID-19 patients in Europe.
  • The Company will now commence the Phase 1 NOXCOVID-1 study.
  • The official approval represents an important medical milestone, with Veyonda® believed to be the first drug tested in COVID-19 patients that inhibits STING pathway.
  • Noxopharm will enrol patients under NOXCOVID-1 study until late-October 2020, anticipating the release of study findings in early-2021.
  • The Company remains in discussion with the US FDA regarding a possible clinical trial in the US, following the review of the NOXCOVID trial data.
non AMP MTF 10th feb webinar

Australian biotech, Noxopharm Limited (ASX:NOX) has announced an important milestone with formal approval for immediate initiation of Veyonda®’s clinical trial in COVID-19 patients in Europe.

Following the key update, the Company’s stock marked an uptick of ~5 per cent to $0.320 on 1 September 2020.

NOXCOVID-1 is a Phase 1 dose-expansion and dose-escalation study, which focuses on safety and proof-of-principle endpoints. The study targets patients who have been admitted to hospital for respiratory insufficiency (not requiring artificial ventilation) connected with the SARS-CoV-2 virus.

In June this year, Noxopharm notified about its plan to commence NOXCOVID clinical program with a Phase 1 trial in Europe, following regulatory approvals. Subsequent to the review, the expert panels have now granted the official approval to start this study in Europe.

Official Approval – An important Milestone

According to Noxopharm, the official approval represents an important medical milestone in being the first known use of a drug in COVID-19 patients that inhibits STING pathway. Excessive STING signalling is increasingly thought to be a leading cause of death and long-term disability in COVID-19 patients.

Noxopharm believes Veyonda® has potential to avert the progression of COVID-19 disease through the STING pathway into the phenomenon termed as a ‘cytokine storm’, resulting in septic shock. Consequently, the Company is in a position to put this theory into practice and possibly help to lessen the dreadful impact of this pandemic.

As per Noxopharm, it appears increasingly that the world is going to have to learn to live with the SARS-CoV-2 virus. This means that there will be a need for effective therapies to cope with ~5 per cent of patients who contract the virus and whose lung failure endangers them of developing a cytokine storm and its related serious clotting disorders.

Given the situation, Noxopharm expects the upcoming NOXCOVID-1 study to potentially place Veyonda® as a front-line therapy for these ~5 per cent of patients, irrespective of whether a safe and effective vaccine is developed.

Must Read! Noxopharm: Latest Data Validates Potential of Veyonda®’s Idronoxil to Turn ‘COLD’ Tumours to ‘HOT’

Details of NOXCOVID-1 Study

The NOXCOVID-1 study will be conducted in around 40 COVID-19 patients admitted to hospitals of Ukraine and Moldova. Both these countries are presently facing high rates of COVID-19 infection and hospitalisation.

Noxopharm has planned to administer a range of doses of Veyonda® to COVID-19 patients, who are hospitalised with moderate symptoms and are at high risk of progressing into a cytokine storm and developing septic shock. While these patients are ill enough to require hospitalisation, they do not have such serious symptoms that they need mechanical ventilation or ICU care.

In the NOXCOVID-1 study, patients will be treated with Noxopharm’s Veyonda® for not less than 14 days and may obtain treatment for up to 28 days if needed. Additionally, the study will measure the following aspects:

  • the safety and tolerability of the medication in patients with poor lung function,
  • the drug’s ability to prevent patients from tipping over into a cytokine storm and septic shock, and
  • the effect of treatment on blood cytokine levels that will be evaluated in an Australian laboratory.

Way Ahead

Noxopharm has already completed training of the medical personnel at the study sites. With the recent receipt of official approval, supplies for the study are also being shipped without any delay. Commencing the NOXCOVID-1 study immediately, Noxopharm will enrol patients until late-October 2020, potentially releasing the study findings in early-2021.

Following the review of final NOXCOVID-1 data, Noxopharm will consider its next step. However, the Company continues to remain in discussion with the US FDA on carrying out a clinical trial in the US, with NOXCOVID-1 serving as a proof-of-principle, pilot study.



The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK